Literature DB >> 19785527

Resistance to rotavirus infection in adult volunteers challenged with a virulent G1P1A[8] virus correlated with serum immunoglobulin G antibodies to homotypic viral proteins 7 and 4.

Lijuan Yuan1, Shinjiro Honma, Inyoung Kim, Albert Z Kapikian, Yasutaka Hoshino.   

Abstract

BACKGROUND: In a study performed in 1983, 18 adult volunteers received oral challenge with the virulent human rotavirus strain D (G1P1A[8],NSP4[B]). To identify correlates of resistance to rotavirus infection, we analyzed levels of serum immunoglobulin (Ig) A and IgG antibodies to various rotaviral antigens in 16 of the 18 volunteers.
METHODS: We used immunocytochemical assays that involved a total of 16 different recombinant baculoviruses, with each baculovirus expressing one of the following major serotype/genotype rotavirus proteins for the serologic assays: (1) viral protein (VP) 4 with P1A[8], P1B[4], P2A[6], P3[9], or P4[10] specificity; (2) VP7 with G1-G4 or G9 specificity; and (3) nonstructural viral protein (NSP) 4 with genotype A, B, C, or D specificity.
RESULTS: The prechallenge titers of IgG antibody to VP7 types G1, G3, G4, and G9; VP4 types P1A[8], P1B[4], P2A[6], and P4[10]; and NSP4 type [A] in the group of noninfected volunteers (n = 11) were significantly higher than those in the group of infected volunteers (n = 5; of these 5 volunteers, 4 were symptomatically infected). Moreover, logistic regression analysis showed that resistance to rotavirus infection most closely correlated with higher prechallenge titers of IgG antibody to homotypic VP7 (G1) and VP4 (P1A[8]).
CONCLUSIONS: These results suggest that protection against rotavirus infection and disease is primarily VP7/VP4 homotypic and, to a lesser degree, heterotypic.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19785527      PMCID: PMC2760642          DOI: 10.1086/606116

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  39 in total

1.  Rotavirus vaccines.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2007-08-10

Review 2.  A hexavalent human rotavirus-bovine rotavirus (UK) reassortant vaccine designed for use in developing countries and delivered in a schedule with the potential to eliminate the risk of intussusception.

Authors:  Albert Z Kapikian; Lone Simonsen; Timo Vesikari; Yasutaka Hoshino; David M Morens; Robert M Chanock; John R La Montagne; Brian R Murphy
Journal:  J Infect Dis       Date:  2005-09-01       Impact factor: 5.226

3.  Quantification of systemic and local immune responses to individual rotavirus proteins during rotavirus infection in mice.

Authors:  S Ishida; N Feng; B Tang; J M Gilbert; H B Greenberg
Journal:  J Clin Microbiol       Date:  1996-07       Impact factor: 5.948

4.  Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants.

Authors:  M L Clements-Mann; M K Makhene; J Mrukowicz; P F Wright; Y Hoshino; K Midthun; E Sperber; R Karron; A Z Kapikian
Journal:  Vaccine       Date:  1999-06-04       Impact factor: 3.641

5.  Viral proteins VP2, VP6, and NSP2 are strongly precipitated by serum and fecal antibodies from children with rotavirus symptomatic infection.

Authors:  J Colomina; M T Gil; P Codoñer; J Buesa
Journal:  J Med Virol       Date:  1998-09       Impact factor: 2.327

6.  Oral administration of human rotavirus to volunteers: induction of illness and correlates of resistance.

Authors:  A Z Kapikian; R G Wyatt; M M Levine; R H Yolken; D H VanKirk; R Dolin; H B Greenberg; R M Chanock
Journal:  J Infect Dis       Date:  1983-01       Impact factor: 5.226

7.  Identification of VP7 epitopes associated with protection against human rotavirus illness or shedding in volunteers.

Authors:  K Y Green; A Z Kapikian
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

8.  Analysis of homotypic and heterotypic serum immune responses to rotavirus proteins following primary rotavirus infection by using the radioimmunoprecipitation technique.

Authors:  S C Richardson; K Grimwood; R F Bishop
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

9.  Characterization of novel VP7, VP4, and VP6 genotypes of a previously untypeable group A rotavirus.

Authors:  Owen D Solberg; Maria Eloisa Hasing; Gabriel Trueba; Joseph N S Eisenberg
Journal:  Virology       Date:  2009-01-08       Impact factor: 3.616

10.  Immunodominance of the VP4 neutralization protein of rotavirus in protective natural infections of young children.

Authors:  R L Ward; M M McNeal; D S Sander; H B Greenberg; D I Bernstein
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

View more
  6 in total

Review 1.  Rotavirus infections and vaccines: burden of illness and potential impact of vaccination.

Authors:  Keith Grimwood; Stephen B Lambert; Richard J Milne
Journal:  Paediatr Drugs       Date:  2010-08-01       Impact factor: 3.022

Review 2.  Rotavirus immune responses and correlates of protection.

Authors:  Juana Angel; Manuel A Franco; Harry B Greenberg
Journal:  Curr Opin Virol       Date:  2012-06-05       Impact factor: 7.090

3.  Parenterally Administered P24-VP8* Nanoparticle Vaccine Conferred Strong Protection against Rotavirus Diarrhea and Virus Shedding in Gnotobiotic Pigs.

Authors:  Ashwin Ramesh; Jiangdi Mao; Shaohua Lei; Erica Twitchell; Ashton Shiraz; Xi Jiang; Ming Tan; And Lijuan Yuan
Journal:  Vaccines (Basel)       Date:  2019-11-06

4.  Molecular characterization of rotavirus isolates from select Canadian pediatric hospitals.

Authors:  Andrew McDermid; Nicole Le Saux; Elsie Grudeski; Julie A Bettinger; Kathy Manguiat; Scott A Halperin; Lily Macdonald; Pierre Déry; Joanne Embree; Wendy Vaudry; Timothy F Booth
Journal:  BMC Infect Dis       Date:  2012-11-15       Impact factor: 3.090

Review 5.  Correlates of protection for rotavirus vaccines: Possible alternative trial endpoints, opportunities, and challenges.

Authors:  Juana Angel; A Duncan Steele; Manuel A Franco
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

6.  Post-vaccine rotavirus genotype distribution in Nairobi County, Kenya.

Authors:  Joshua Ndung'u Gikonyo; Betty Mbatia; Patrick W Okanya; George F O Obiero; Carlene Sang; Duncan Steele; James Nyangao
Journal:  Int J Infect Dis       Date:  2020-09-06       Impact factor: 3.623

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.